Physician

Andrew Hong Lu, M.D.

According to 2025 Medicare claims, Andrew Lu, M.D. (NPI: 1356890560) practices hematology/oncology in the Newark, NJ market, with the plurality of this provider's patient population coming from Essex, NJ. This provider's primary affiliated billing organization is SUMMIT MEDICAL GROUP PA (NPI: 1942254347; TIN: 223487984) and primary practice location at 07013-3398. Lu is affiliated with the Summit Health ACO (ACO ID: A5049), participating under the MSSP model.

Lu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 244 traditional Medicare patients, billed 33,773 HCPCS/CPT codes, and received $537,791 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 424 prescription claims across 108 beneficiaries totaling $1,250,960 in drug costs, led by Jakafi (Ruxolitinib Phosphate). 2020 DME data shows 27 claims. Open Payments data shows 1 records totaling $100. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $19,968 to $537,791. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,356 to $1,250,960. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	88	281	$19,968
2018	381	1,062	$82,377
2019	223	487	$36,890
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	63	7,650	$47,383
2023	183	17,527	$321,834
2024	244	33,773	$537,791

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	23	$1,356
2018	29	53	$3,155
2019	37	91	$318,838
2020	33	144	$529,128
2021	42	119	$521,699
2022	50	186	$1,006,022
2023	40	148	$270,030
2024	108	424	$1,250,960

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	33	$1,394
2020	N/R	27	$957
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	64	64	$172
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	147	365	$149
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	66	76	$109
36415	Insertion of needle into vein for collection of blood sample	70	183	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	61	148	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	23	690	$398,201
Kisqali	Ribociclib Succinate	11	308	$169,331
Eliquis	Apixaban	36	2,055	$37,817
Xarelto	Rivaroxaban	13	1,050	$18,521
Letrozole	Letrozole	41	2,730	$868

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$100	Incyte Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andrew Hong Lu, M.D.?

Tedicare shows public-source Medicare data for Andrew Hong Lu, M.D. (NPI 1356890560), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrew Hong Lu, M.D. have ACO affiliation data?

Andrew Hong Lu, M.D. is shown with ACO affiliation data for Summit Health ACO (MSSP, ACO ID A5049).

What billing organization is linked to Andrew Hong Lu, M.D.?

Andrew Hong Lu, M.D. is linked to SUMMIT MEDICAL GROUP PA (billing NPI 1942254347) in the available physician profile data.

Does Andrew Hong Lu, M.D. have Open Payments data?

Andrew Hong Lu, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.